Dale Shepard
Overview
Explore the profile of Dale Shepard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
262
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen J, Vincent M, Shepard D, Peereboom D, Mahalingam D, Battiste J, et al.
Commun Med (Lond)
. 2024 May;
4(1):95.
PMID: 38773224
Background: Preclinical studies have demonstrated that VT1021, a first-in-class therapeutic agent, inhibits tumor growth via stimulation of thrombospondin-1 (TSP-1) and reprograms the tumor microenvironment. We recently reported data from the...
2.
Sommovilla J, Shepard D, Liska D
Clin Colon Rectal Surg
. 2024 Apr;
37(3):185-190.
PMID: 38606047
Desmoid disease, though technically a benign condition, is nevertheless a leading cause of morbidity and mortality in patients with familial adenomatous polyposis (FAP). Desmoid disease impacts approximately 30% of FAP...
3.
Kamath S, Roopkumar J, Ni Y, Shen M, Bejarano P, Allende D, et al.
Oncology (Williston Park)
. 2023 Dec;
37(12):488-495.
PMID: 38133563
Introduction: Exceptional response to therapy is rare in patients with advanced pancreatic cancer. This study explored potential genomic differences between typical and exceptional responses that could confer more favorable biology....
4.
Somasundaram E, Smile T, Halima A, Broughman J, Reddy C, Parsai S, et al.
J Radiosurg SBRT
. 2023 Jul;
8(4):265-273.
PMID: 37416333
Introduction: Stereotactic body radiation therapy (SBRT) is increasingly utilized for patients with recurrent and metastatic sarcoma. SBRT affords the potential to overcome the relative radioresistance of sarcomas through delivery of...
5.
Asha W, Koro S, Mayo Z, Yang K, Halima A, Scott J, et al.
Am J Clin Oncol
. 2023 Mar;
46(6):263-270.
PMID: 36914598
Background: Lung metastases are the most common form of distant failure for patients diagnosed with sarcoma with metastasectomy considered for some patients with limited metastatic disease and good performance status....
6.
Hasan S, Witten J, Collier P, Tong M, Pettersson G, Smedira N, et al.
JTCVS Open
. 2022 Aug;
8:384-390.
PMID: 36004100
Objective: To evaluate the outcomes of surgical resection of malignant primary cardiovascular tumors. Methods: From 1983 to 2018, 32 patients underwent surgical resection of malignant primary cardiovascular sarcoma at Cleveland...
7.
James A, Smith C, Litzow M, Perl A, Altman J, Shepard D, et al.
Clin Pharmacokinet
. 2021 Jul;
60(9):1251.
PMID: 34297319
No abstract available.
8.
Wang T, Mukherjee S, Tan C, Shepard D, Pettersson G, Desai M
Circ Cardiovasc Imaging
. 2020 Nov;
13(12):e010783.
PMID: 33238725
No abstract available.
9.
Sohal D, Krishnamurthi S, Tohme R, Gu X, Lindner D, Landowski T, et al.
Am J Cancer Res
. 2020 Oct;
10(9):3047-3060.
PMID: 33042633
DNA methyltransferase 1 (DNMT1) is scientifically validated as a molecular target to treat chemo-resistant pancreatic ductal adenocarcinoma (PDAC). Results of clinical studies of the pyrimidine nucleoside analog decitabine to target...
10.
James A, Smith C, Litzow M, Perl A, Altman J, Shepard D, et al.
Clin Pharmacokinet
. 2020 Apr;
59(10):1273-1290.
PMID: 32304015
Background And Objective: Gilteritinib is a novel, highly selective tyrosine kinase inhibitor approved in the USA, Canada, Europe, Brazil, Korea, and Japan for the treatment of FLT3 mutation-positive acute myeloid...